Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. (NYSE: ZTS) is described as the world’s leading animal health company, and the ZTS news feed on Stock Titan brings together company announcements, regulatory updates and product developments that shape its story. Zoetis focuses on medicines, vaccines, diagnostics and technologies for animals, serving veterinarians, pet owners and livestock producers in over 100 countries.
News items for Zoetis often highlight its research and development activities and regulatory milestones. Recent releases include Health Canada approval for Portela (relfovetmab injection) to alleviate pain associated with osteoarthritis in cats and European Commission marketing authorization for Lenivia (izenivetmab) to reduce osteoarthritis pain in dogs. These updates illustrate Zoetis’ emphasis on monoclonal antibody therapies and long-acting pain management solutions for companion animals.
Investors can also follow financial and capital markets news, such as announcements of convertible senior notes offerings, senior notes issuances and the use of proceeds for share repurchases and capped call transactions. The company regularly reports dividends declared by its board of directors and provides quarterly and annual financial results through press releases and Form 8-K filings.
Zoetis participates in major healthcare conferences and hosts webcasts, including innovation-focused events that discuss its pipeline across chronic kidney disease, oncology, cardiology, osteoarthritis pain and dermatology. These events, along with earnings calls and conference presentations, are frequently covered in the news stream.
By monitoring the ZTS news page, readers can review product approvals, R&D updates, capital allocation decisions, credit facility arrangements and governance developments reported by Zoetis. This page can be revisited to see how new therapies, financial actions and strategic communications are disclosed over time.
Zoetis Foundation has announced a $3 million grant to the American Red Cross, to be used over six years for global disaster relief efforts. This grant will support the Annual Disaster Giving Program, aiding both domestic and international disaster response and preparedness. In addition, Zoetis has launched a consumer matching campaign with American Humane to support pets affected by natural disasters in the U.S.
Zoetis has a decade-long partnership with American Humane, focusing on animal safety in disaster situations, and they have contributed to the care of 1.3 million animals globally between 2021-2023. The collaboration includes operating emergency vehicles stocked with Zoetis pet medications and hosting pet preparedness clinics.
The Zoetis Foundation’s support aims to bolster the Red Cross' ability to respond to disasters and help communities prepare for future crises. This initiative is part of Zoetis' broader sustainability strategy, which has made significant impacts worldwide.
Zoetis released its 2023 Sustainability Report, highlighting advancements in its 'Driven to Care' strategy. Key achievements include:
1. Increasing volunteer work by 81% to 16,611 hours.
2. Supporting 28 initiatives with $8.3 million in grants across 19 countries.
3. Launching innovative diagnostics, vaccines, and parasiticides for livestock producers.
4. Utilizing over 30% renewable electricity with on-site solar arrays at seven facilities, aiming for 100% by 2030.
5. Replacing rabies vaccine packaging plastic with paperboard, reducing PVC use by 8.0 metric tons annually.
Zoetis invested $7 million in community programs, reaching 202,000 pet owners and impacting 91,000 animals. The company also received eight awards for fostering an inclusive culture and expanded its Leading@Zoetis program to over 2,000 leaders globally.
Zoetis aims to achieve carbon neutrality by 2030, reporting 32.6% renewable electricity use, completing 38 energy efficiency projects, and reducing Scope 1 and 2 emissions by 18.9% since 2021.
The Board of Directors at Zoetis (NYSE: ZTS) has announced a dividend of $0.432 per share for the third quarter of 2024.
This dividend will be disbursed on September 4, 2024, to all shareholders of record as of July 18, 2024. The company continues its commitment to returning value to its shareholders through regular dividend payments.
Zoetis (NYSE: ZTS) will attend the William Blair 44th Annual Growth Stock Conference on June 4, 2024.
Wetteny Joseph, Executive Vice President and CFO, will represent the company and answer analysts' questions. His presentation is scheduled for 2:40 p.m. CT.
Investors and interested parties can access the live audio webcast of the presentation via the Zoetis investor relations website. A replay will be available following the event.
Zoetis (NYSE: ZTS) will participate in the Stifel 2024 Jaws and Paws Conference on May 29, 2024. Kristin Peck, CEO, will represent the company and respond to analysts' questions. Her presentation is scheduled for 12:05 p.m. ET and will be available via a live audio webcast on the Zoetis investor website. A replay will also be accessible after the event.
Zoetis Inc. (NYSE:ZTS) reported a successful first quarter of 2024 with revenue of $2.2 billion, a 10% increase YoY. Net income was $599 million, or $1.31 per diluted share, up 9% and 10%, respectively. Adjusted net income was $634 million, or $1.38 per diluted share. The company updated its full-year 2024 revenue guidance to $9.050 - $9.200 billion, showing operational revenue growth of 8.5% to 10.5%. Zoetis continues to invest in innovation and growth, expanding product franchises globally.
FAQ
What is the current stock price of Zoetis (ZTS)?
What is the market cap of Zoetis (ZTS)?
